Objectives
To evaluate the effectiveness of antibiotics for bronchiolitis in children under two years of age compared to placebo or other interventions.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2014, Issue 6) , which includes the Cochrane Acute Respiratory Infection Group's Specialised Register, and the Database of Abstracts of Reviews of Effects, MEDLINE (1966 to June 2014 , EMBASE (1990 to June 2014 ) and Current Contents (2001 to June 2014 .
Selection criteria
Randomised controlled trials (RCTs) comparing antibiotics to placebo in children under two years diagnosed with bronchiolitis, using clinical criteria (including respiratory distress preceded by coryzal symptoms with or without fever). Primary clinical outcomes included time to resolution of signs or symptoms (pulmonary markers included respiratory distress, wheeze, crepitations, oxygen saturation and fever). Secondary outcomes included hospital admissions, length of hospital stay, readmissions, complications or adverse events and radiological findings.
Data collection and analysis
Two review authors independently analysed the search results.
Main results
We included seven studies with a total of 824 participants. The results of these seven included studies were often heterogeneous, which generally precluded meta-analysis, except for deaths, length of supplemental oxygen use and length of hospital admission.
In this update, we included two new studies (281 participants), both comparing azithromycin with placebo. They found no significant difference for length of hospital stay, duration of oxygen requirement and readmission. These results were similar to an older study (52 participants) that demonstrated no significant difference comparing ampicillin and placebo for length of illness.
One small study (21 participants) with higher risk of bias randomised children with proven RSV infection to clarithromycin or placebo and found a trend towards a reduction in hospital readmission with clarithromycin.
The three studies providing adequate data for days of supplementary oxygen showed no difference between antibiotics and placebo (pooled mean difference (MD) (days) -0.20; 95% confidence interval (CI) -0.72 to 0.33). The three studies providing adequate data for length of hospital stay, similarly showed no difference between antibiotics (azithromycin) and placebo (pooled MD (days) -0.58; 95% CI -1.18 to 0.02).
Two studies randomised children to intravenous ampicillin, oral erythromycin and control and found no difference for most symptom measures.
There were no deaths reported in any of the arms of the seven included studies. No other adverse effects were reported.
Authors' conclusions
This review did not find sufficient evidence to support the use of antibiotics for bronchiolitis, although research may be justified to identify a subgroup of patients who may benefit from antibiotics. Further research may be better focused on determining the reasons that clinicians use antibiotics so readily for bronchiolitis, how to reduce their use and how to reduce clinician anxiety about not using antibiotics.
P L A I N L A N G U A G E S U M M A R Y

Antibiotics for bronchiolitis in children under two years of age Question
We reviewed the evidence on the effect of antibiotics on clinical outcomes in children with bronchiolitis.
Background
Bronchiolitis is a serious respiratory illness that affects babies. It is most commonly caused by respiratory syncytial virus (RSV) and is the most common reason for hospitalisation in babies younger than six months. Babies usually present with runny nose, cough, shortness of breath and signs of difficulty in breathing, which can become life-threatening. Despite its viral cause, antibiotics are often prescribed. Prescribers may be expecting benefits from anti-inflammatory effects attributed to some antibiotics or be concerned about secondary bacterial infection, particularly in children who are very unwell and require intensive care. We wanted to discover if antibiotics improved or worsened clinical outcomes in children with bronchiolitis.
Study characteristics
This evidence is current to June 2014. We identified seven trials (824 participants) comparing antibiotics with placebo or no antibiotics in children with bronchiolitis. Two of these studies also compared intravenous and oral antibiotics.
Key results
Our primary outcome was duration of symptoms/signs (duration of supplementary oxygen requirement, oxygen saturation, wheeze, crepitations (crackles), fever). Secondary outcomes included duration of admissions/time to discharge from hospital, readmissions, complications/adverse events (including death) and radiological (X-ray) findings.
We included seven studies with a total of 824 participants. Four studies reported on duration of supplementary oxygen requirement and did not demonstrate a significant difference in the duration of oxygen use comparing antibiotics to placebo. We combined three studies comparing azithromycin versus placebo and again did not demonstrate a significant difference between antibiotics and placebo in the duration of oxygen requirement. Most of the included studies did not report on the primary outcomes of wheeze, crepitations and fever. One study with a high risk of bias found mixed results for the effects of antibiotics on wheeze but no difference for other symptom measures. One study found no difference in duration of fever and one study found no difference in presence of fever on day two.
In regards to secondary outcomes, six included studies did not find any difference between antibiotics and placebo for the outcomes of length of illness or length of hospital stay. For length of hospital stay, we combined data from three studies comparing the use of azithromycin versus placebo as a subtotal as part of the overall analysis of the effect of antibiotics on hospital stay. These combined results similarly showed no difference between antibiotics (azithromycin) and placebo. One small study with a high risk of bias found that three weeks of clarithromycin significantly reduced hospital readmission compared to placebo. However, this reduction in hospital readmissions was not replicated in a more recent study that randomised 97 children to receive either a single large dose of azithromycin or placebo. There were no deaths reported in any arms of any of the seven included trials and none of the studies specifically reported on adverse effects of antibiotics. Only two studies made general comments that no adverse effects were found with antibiotic use. Radiological findings were not reported as an outcome in any of the included studies.
Quality of the evidence
This 2014 updated review is stronger, owing to the inclusion of two new randomised controlled trials (RCTs). These two studies combined involved a further 138 participants in the antibiotic arm and 143 participants in the placebo arm. Prior to this only three small RCTs had examined antibiotics versus placebo, with only 72 participants in the antibiotic arms and 72 participants in the placebo arms. Consequently, this review makes a substantial contribution, especially with regards to the role of macrolides, such as azithromycin, in bronchiolitis. No new unpublished data have been included. However, the review authors have no reason to suspect that the search strategy has biased the review results. Raw data could not be obtained from one study conducted 40 years ago, nor from three other trials, which is a weakness of this review. Three trial authors did provide raw data for this review.
Conclusion
This review did not find sufficient evidence to support the use of antibiotics for bronchiolitis. Research may be justified to identify a subgroup of patients who may benefit from antibiotics.
B A C K G R O U N D
Description of the condition
Bronchiolitis is a serious, potentially life-threatening respiratory illness that often affects young babies. It occurs most frequently in the first year of life and is the commonest cause of hospital admissions in infants under six months of age (Wohl 1978) . The most commonly identified pathogen is respiratory syncytial virus (RSV). Other viruses such as human meta-pneumovirus (HMPV), influenza, parainfluenza, adenovirus and rhinovirus have also been implicated (Williams 2004) . Other less common pathogens include Mycoplasma pneumoniae (M. pneumoniae), which can occur in sporadic outbreaks (Glezen 1971; Rose 1987) . The diagnosis is most often made on clinical grounds, which usually includes tachypnoea (rapid breathing) and wheezing in children under two years of age (Bordley 2004) . Immunofluorescence and culture of the nasopharyngeal aspirate may be used to determine the causative organism and may reduce antibiotic use (Christakis 2005) . A chest X-ray may show hyperinflation and patchy atelectasis (where parts of the lung collapse or do not inflate properly) (Smyth 2006) . There are few effective therapies, including antiviral therapies (Smyth 2006) .
Description of the intervention
Antibiotics are not recommended unless there is concern about complications such as secondary bacterial pneumonia (Fitzgerald 2004; Lozano 2002) . This is based on evidence suggesting a low risk of bacteraemia (0.2%) in children with bronchiolitis and fever -a lower risk than for children with a fever without a recognisable illness, where the rate ranges from 2% to 7% (Greenes 1999) . Antibiotic use comes with significant harms including common adverse reactions (rash, abdominal pain, diarrhoea and vomiting), cost and community bacterial resistance (Brook 1998 
How the intervention might work
Antibiotics may be useful in cases of illness where superinfection with bacteria occurs, although it is unlikely that antibiotics will be effective for a condition that only has a viral cause. However, some antibiotics may have anti-inflammatory effects, which may improve symptoms.
Why it is important to do this review
The use of antibiotics for uncomplicated bronchiolitis is common yet is not justified by our understanding of bronchiolitis as a viral illness. The discord between clinical practice and the pathophysiological understanding of bronchiolitis as a viral illness will benefit from the empirical evidence offered by this systematic review.
O B J E C T I V E S
M E T H O D S
Criteria for considering studies for this review
Types of studies
Single or double-blind randomised controlled trials (RCTs) comparing antibiotics to placebo or control to treat bronchiolitis.
Types of participants
Children under the age of two years diagnosed with bronchiolitis using clinical criteria, such as respiratory distress preceded by coryzal symptoms, with or without fever.
Types of interventions
Oral, intravenous, intramuscular or inhaled antibiotics versus placebo. We used multiple strategies to identify as many trials as possible that met the inclusion criteria, regardless of language or publication status. We used the search strategy described in Appendix 1 to search MEDLINE and CENTRAL. We combined the MED-LINE search strategy with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity-and precision-maximising version (2008 revision): Ovid format (Lefebvre 2011). We modified these terms to search EMBASE (Appendix 2) and Current Contents (Appendix 3).
Types of outcome measures
Searching other resources
We searched the trials registries WHO ICTRP and ClinicalTrials.gov for completed and ongoing trials (latest search date 7 July 2014). We handsearched the references of all identified studies. One review author (GS) and an expert librarian (LE) carried out the search. We contacted experts in the field looking for unpublished studies.
Data collection and analysis
Selection of studies
In the original publication of this review, two review authors (GS, CDM) independently scanned abstracts from the initial search results to identify trials that loosely met the inclusion criteria. Two review authors (CDM, JD) independently reviewed the full-text articles of the retrieved trials and applied the inclusion criteria.
In the 2011 update, four further studies were found to meet the inclusion criteria and two review authors (CDM, JD) independently assessed the methodological quality of the new included studies that met the inclusion criteria at that time. Similarly, in this updated review two authors (RF, GS) scanned abstracts from the updated searches to identify trials that met the inclusion criteria. Two review authors (CDM, GS) independently reviewed the full-text articles of the retrieved trials and applied the inclusion criteria. We identified two new papers, Pinto 2012 and McCallum 2013, for inclusion in this 2014 updated review.
Data extraction and management
In the initial publication of this review, two review authors (CDM, JD) independently extracted data from each study to be included, using data extraction forms which included type of intervention, adverse events, and continuous and dichotomous outcomes. We also noted the setting (hospital or primary care), study population and any additional interventions or tests. In this update two review authors (CDM, GS) independently extracted data from the two new included papers. We contacted the authors of both papers to obtain original data.
Assessment of risk of bias in included studies
We rated the quality of each eligible RCT according to the 'Risk of bias' tool available in RevMan 2014 and criteria set out in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We assessed methodological quality under the headings of allocation, blinding, incomplete outcome data, selective reporting and other potential sources of bias. Two review authors (GS, CDM) independently assessed the methodological quality of the two new included trials for this review update. We resolved any disagreements between the review authors by discussion.
Measures of treatment effect
We analysed data using RevMan 5.3 (RevMan 2014). We expressed continuous data comparisons using mean differences (MD), where there was one study, or standardised mean difference (SMD), where more than one study used different measurement scales. We expressed dichotomous data using odds ratios (OR).
We pooled data into clinical outcomes where multiple trial results for the same clinical presentation existed and heterogeneity did not preclude pooling of results.
Unit of analysis issues
The unit of analysis for each outcome was the individual research participant.
Dealing with missing data
Intention-to-treat (ITT) analyses were conducted in Kneyber 2008 and Kabir 2009. In the other five included studies it is not clear if ITT analyses were carried out. Studies were checked for missing data and attempts were made to contact study authors regarding missing data.
Assessment of heterogeneity
We did not undertake a meta-analysis for most clinical outcomes owing to multiple analyses with only one or two study results. We pooled results where we found a satisfactorily low I 2 statistic and non-significant Chi 2 test results. We were only able to combine data for deaths, duration of supplementary oxygen use and length of hospital stay. Given there were no deaths we cannot assess heterogeneity for that outcome.
Assessment of reporting biases
Studies were assessed to ensure that outcomes specified in the methods sections of included studies were reported in the results sections.
Data synthesis
We undertook meta-analysis for outcomes where there were sufficient comparable data. Only three outcomes fitted this bill: deaths, duration of supplemental oxygen use and length of hospital stay. We were not able to combine symptom measures owing to a lack of comparability of outcome measures or because the timing of measurement was irreconcilably different. We undertook narrative synthesis of the majority of results.
Subgroup analysis and investigation of heterogeneity
Where there was significant heterogeneity we did not conduct meta-analysis. Sub group analysis to investigate heterogeneity was considered for groups including year of publication, types of antibiotics used and hospital versus community setting.
Sensitivity analysis
Not applicable. 
R E S U L T S
Excluded studies
Boogaard 2007 did not study antibiotics for bronchiolitis. We excluded one study because it dealt with both pneumonia and bronchiolitis using crepitations and radiography as criteria for patient selection (Friis 1984) . The study did perform a subgroup analysis of the two groups (antibiotics and placebo) based on virological diagnosis and these results are discussed.
Risk of bias in included studies
Risk of bias is summarised in Figure 1 and Figure 2 . 
Incomplete outcome data
In the Mazumder 2009 trial, 22 participants (out of 124) were excluded because they did not attend regular follow-up (18) or were persistently unwell. In the Kabir 2009 trial, 17 children were referred to tertiary care where there was access to paediatric intensive care and for 15 children their parents withdrew or they left their respective hospitals. In Tahan 2007, nine participants were excluded because they took corticosteroids. There were only 15 participants in each group and six were excluded from the placebo group for taking corticosteroids and three from the clarithromycin group. In Field 1966, eight patients were excluded from the study owing to symptom severity (three from the ampicillin group and five from the placebo group) with an extra two participants (one from each group) lost to follow-up at the end of the trial. There were no drop outs from the Kneyber 2008 trial. Only one patient was lost to follow-up in the Pinto 2012 trial. There was no loss to follow-up for the outcome of respiratory readmission in the McCallum 2013 trial. One participant was excluded from analysis for the outcomes of length of stay and oxygen use as they were randomised to the placebo group but received a macrolide within the exclusion timeframe (McCallum 2013).
Selective reporting
We found Kabir 2009 to have a high risk of reporting bias.
Other potential sources of bias
We identified no other concerns.
Effects of interventions
Duration of symptoms/signs 
Oxygen saturation
Mazumder 2009 randomised infants younger than 24 months (and older than one month) with clinically suspected bronchiolitis to intravenous ampicillin (29 children), oral erythromycin (32 children) and no antibiotics (43 children). Symptoms (wheeze, shortness of breath, oxygen saturation less than 96%, lack of social smile and feeding difficulties) were measured on days one, three and five. No significant differences were reported between the three groups for oxygen saturation less than 96%. Full results as reported by this study for the three groups are tabled with Chi 2 test results and significance levels ( Table 2 ). The two antibiotic arms of this trial were also combined and compared with control. Again there was no significant difference between antibiotics and control for the outcome of oxygen saturation less than 96%.
Wheeze
Mazumder 2009 found there were significantly fewer children with wheeze in the oral erythromycin group on day three but significantly fewer children with wheeze in the control group on day five. When the two antibiotic arms of this trial were combined and compared with control, for the outcome of wheeze on day three, significantly fewer children had wheeze in the antibiotics arm (odds ratio (OR) 0.27; 95% CI 0.12 to 0.62). However, on day five significantly more children in the antibiotics arm had wheeze compared with control (OR 5.55; 95% CI 1.18 to 26.05) (Analysis 2.1).
Crepitations
None of the included studies explored this outcome.
Fever
Kabir 2009 randomised infants younger than 24 months with clinical signs of bronchiolitis (hospitalised with runny nose, cough, breathing difficulty, chest indrawing and rhonchi on auscultation). Symptom resolution was measured as rapid (less than four days) or gradual (more than four days). None of the symptom measures (including fever on day two) differed significantly between parenteral ampicillin, oral erythromycin and control (Table 3) . There was no significant difference found in duration of fever (days) in Kneyber 2008 when comparing azithromycin versus placebo (Table 1) 
Readmissions
In Tahan 2007, one participant was readmitted in the clarithromycin group (8.3%) and four in the placebo group (44%).
McCallum 2013 explored hospital respiratory readmissions six months post discharge as a primary outcome. The number of children readmitted was similar, with 10 per group (OR 0.93; 95% CI 0.35 to 2.47). These two studies providing sufficient data to compare hospital readmissions found no significant difference but we did not pool data owing to a substantial risk of heterogeneity (I 2 statistic = 59%) (McCallum 2013; Tahan 2007) .
Complications/adverse events developed, including death
There were no deaths reported in any arms of any of the seven included trials.
Radiological findings
Radiological findings were not reported as an outcome in any of the included studies.
D I S C U S S I O N
Summary of main results
Six included studies did not find any difference between antibiotics and placebo for their primary outcomes of length of illness (Field 1966) 
Quality of the evidence
This 2014 update saw the addition of two larger studies examining azithromycin versus placebo for bronchiolitis (McCallum 2013; Pinto 2012) . These two studies combined involved a further 138 participants in the antibiotic arm and 143 participants in the placebo arm and demonstrated no statistically significant benefit of azithromycin compared to placebo for their primary outcomes. Prior to this only three small RCTs had examined antibiotics versus placebo, with only 72 participants in the antibiotic arms and 72 participants in the placebo arms. The two previous studies describing adequate randomisation conducted in high-income countries did not find any difference between antibiotic and placebo arms (Field 1966; Kneyber 2008) . The study which found clarithromycin more likely to reduce hospital admission than placebo did not adequately describe randomisation nor allocation concealment and 30% of those randomised were excluded owing to co-administration of corticosteroids (Tahan 2007). The inconsistency of results seems most likely to be owing to the differences in methodological quality. The study by Tahan 
Potential biases in the review process
Agreements and disagreements with other studies or reviews
Excluded studies comparing antibiotics to placebo in participants with bronchiolitis did not find any significant difference (Friis 1984).
A U T H O R S ' C O N C L U S I O N S
Implications for practice
Overall, this review does not support the use of antibiotics for bronchiolitis. Antibiotics may be justified in children with bronchiolitis who have respiratory failure.
Implications for research
Research to identify a possible small subgroup of patients presenting with bronchiolitis-like symptoms who may benefit from antibiotics is justified. These might include those with respiratory failure, in intensive care, with nosocomially acquired respiratory syncytial virus (RSV) and with cyanotic congenital heart disease. Future research may include subgroups based on tests for specific pathogens. Otherwise, research may be better focused on determining the reasons that clinicians use antibiotics so readily for bronchiolitis and how to reduce use of antibiotics for bronchiolitis, as well as ways to reduce clinician anxiety about not using antibiotics. We would like to acknowledge Dr Kit Fonseka who co-wrote the initial protocol, reviewed the search results, performed quality appraisal, extracted data and helped write the first version of this review. Jenny Doust gave advice on performing the systematic review, critically appraised primary data, extracted data and helped write the protocol and the first two versions of this review. The patient selection criteria were fine crepitations or consolidation on chest radiograph, which was not consistent with our inclusion criteria of a purely clinical presentation of bronchiolitis 
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